| (R)-SCH 546738 |
|
|
|
|
|
|
|
99.75% |
| (R,R)-CXCR2-IN-2 |
|
|
|
|
|
|
|
99.37% |
| (Rac)-Reparixin |
|
|
|
|
|
|
|
99.75% |
| (Rac)-SCH 563705 |
|
|
|
|
|
|
|
99.78% |
| (S)-SCH 563705 |
|
|
|
|
|
|
|
99.94% |
| (±)-AMG 487 |
|
|
|
|
|
|
|
|
| (±)-NBI-74330 |
|
|
|
|
|
|
|
99.12% |
| Nicotinamide N-oxide-d4 |
|
|
|
|
|
|
|
|
| 4-Amino-D-phenylalanine |
|
|
|
|
|
|
|
99.74% |
| ABX-IL8 |
|
|
|
|
|
|
|
98.70% |
| Ac-Pro-Gly-Pro-OH |
|
|
|
|
|
|
|
99.49% |
| ACKR3 agonist 1 |
|
|
|
|
|
|
|
|
| ACT-1004-1239 |
|
|
|
|
|
|
|
98.81% |
| ACT-660602 |
|
|
|
|
|
|
|
99.02% |
| ACT-672125 |
|
|
|
|
|
|
|
|
| ACT-777991 |
|
|
|
|
|
|
|
99.49% |
| Adakitug |
|
|
|
|
|
|
|
≥99.0% |
| ALX 40-4C |
|
|
|
|
|
|
|
|
| ALX 40-4C Trifluoroacetate |
|
|
|
|
|
|
|
99.78% |
| ALX-0651 |
|
|
|
|
|
|
|
|
| AMD 3329 octahydrobromide |
|
|
|
|
|
|
|
|
| AMD 3465 |
|
|
|
|
|
|
|
98.24% |
| AMD 3465 hexahydrobromide |
|
|
|
|
|
|
|
98.0% |
| AMD-3329 |
|
|
|
|
|
|
|
|
| AMG 487 |
|
|
|
|
|
|
|
99.89% |
| AMG 487 (S-enantiomer) |
|
|
|
|
|
|
|
99.94% |
| Anditixafortide |
|
|
|
|
|
|
|
99.99% |
| Anti-CD185/CXCR5 Antibody |
|
|
|
|
|
|
|
97.41% |
| Anti-CXC-ELR Antibody |
|
|
|
|
|
|
|
|
| Anti-CXCL12/SDF1a Antibody |
|
|
|
|
|
|
|
≥99.0% |
| Anti-CXCL13 Antibody |
|
|
|
|
|
|
|
|
| Anti-CXCL4/PF4 Antibody |
|
|
|
|
|
|
|
95.15% |
| Anti-CXCL8/IL-8 Antibody |
|
|
|
|
|
|
|
99.51% |
| Anti-CXCR2 Antibody |
|
|
|
|
|
|
|
|
| Anti-CXCR3 Antibody (5H7) |
|
|
|
|
|
|
|
|
| Anti-CXCR3/GPR9/CD183 Antibody |
|
|
|
|
|
|
|
98.45% |
| Anti-CXCR4/CD184 Antibody |
|
|
|
|
|
|
|
97.08% |
| Anti-Human/Monkey CXCR4 Antibody (12G5) |
|
|
|
|
|
|
|
|
| Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5) |
|
|
|
|
|
|
|
99.33% |
| Anti-Mouse ACKR4 Antibody (A4Mab-3) |
|
|
|
|
|
|
|
|
| Anti-Mouse CCL5 Antibody (R6G9) |
|
|
|
|
|
|
|
97.24% |
| Anti-Mouse CXCL10 Antibody (1F11) |
|
|
|
|
|
|
|
97.56% |
| Anti-Mouse CXCL16 Antibody (12-81) |
|
|
|
|
|
|
|
97.425% |
| Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) |
|
|
|
|
|
|
|
95.00% |
| Anti-Mouse CXCR2 Antibody (Cx2Mab-1) |
|
|
|
|
|
|
|
|
| Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) |
|
|
|
|
|
|
|
99% |
| Anti-Mouse CXCR4 Antibody (Cx4Mab-1) |
|
|
|
|
|
|
|
|
| Anti-Mouse CXCR6 Antibody (Cx6Mab-1) |
|
|
|
|
|
|
|
99.32% |
| Anti-Mouse/Human CXCL12 Antibody (K15C) |
|
|
|
|
|
|
|
99.57% |
| Antileukinate |
|
|
|
|
|
|
|
|
| AT009 |
|
|
|
|
|
|
|
|
| ATI-2341 |
|
|
|
|
|
|
|
99.64% |
| ATI-2341 TFA |
|
|
|
|
|
|
|
98.08% |
| AZ10397767 |
|
|
|
|
|
|
|
|
| AZD-5069 |
|
|
|
|
|
|
|
99.91% |
| AZD8309 |
|
|
|
|
|
|
|
99.98% |
| Balixafortide |
|
|
|
|
|
|
|
98.20% |
| Balixafortide TFA |
|
|
|
|
|
|
|
99.89% |
| BAM-12P |
|
|
|
|
|
|
|
|
| BC-1485 |
|
|
|
|
|
|
|
|
| BMS-986184 |
|
|
|
|
|
|
|
|
| BPRCX 714 |
|
|
|
|
|
|
|
|
| BPRCX807 |
|
|
|
|
|
|
|
|
| Burixafor hydrobromide |
|
|
|
|
|
|
|
99.70% |
| BVT173187 |
|
|
|
|
|
|
|
99.97% |
| Catenarin |
|
|
|
|
|
|
|
|
| CAY10594 |
|
|
|
|
|
|
|
98.64% |
| CCR5/CXCR3-IN-1 |
|
|
|
|
|
|
|
|
| CCR7 antagonist 1 |
|
|
|
|
|
|
|
99.55% |
| CCX-777 |
|
|
|
|
|
|
|
98.47% |
| CCX-777 formic |
|
|
|
|
|
|
|
98.01% |
| CCX662 |
|
|
|
|
|
|
|
|
| cGAS-IN-9 |
|
|
|
|
|
|
|
|
| COG112 |
|
|
|
|
|
|
|
|
| Corydalmine hydrochloride |
|
|
|
|
|
|
|
|
| Cosalane |
|
|
|
|
|
|
|
99.50% |
| CTCE-0214 |
|
|
|
|
|
|
|
99.96% |
| CTCE-9908 |
|
|
|
|
|
|
|
99.54% |
| CTCE-9908 TFA |
|
|
|
|
|
|
|
|
| CX4338 |
|
|
|
|
|
|
|
|
| CXCL-CXCR1/2-IN-1 |
|
|
|
|
|
|
|
99.64% |
| CXCL12 ligand 1 |
|
|
|
|
|
|
|
|
| CXCL8 (54-72) |
|
|
|
|
|
|
|
99.90% |
| CXCL9(74-103) |
|
|
|
|
|
|
|
|
| CXCR1 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Cxcr1 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Cxcr1 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| CXCR2 antagonist 10 |
|
|
|
|
|
|
|
|
| CXCR2 antagonist 2 |
|
|
|
|
|
|
|
99.32% |
| CXCR2 antagonist 3 |
|
|
|
|
|
|
|
|
| CXCR2 antagonist 4 |
|
|
|
|
|
|
|
|
| CXCR2 antagonist 5 |
|
|
|
|
|
|
|
|
| CXCR2 antagonist 6 |
|
|
|
|
|
|
|
|
| CXCR2 antagonist 7 |
|
|
|
|
|
|
|
|
| CXCR2 antagonist 8 |
|
|
|
|
|
|
|
98.38% |
| CXCR2 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Cxcr2 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| CXCR2 Probe 1 |
|
|
|
|
|
|
|
|
| Cxcr2 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| CXCR2-IN-1 |
|
|
|
|
|
|
|
99.54% |
| CXCR2-IN-2 |
|
|
|
|
|
|
|
99.52% |
| CXCR2-IN-3 |
|
|
|
|
|
|
|
|
| CXCR2/CCR7 antagonist-1 |
|
|
|
|
|
|
|
|
| CXCR3 antagonist 1 |
|
|
|
|
|
|
|
98.6% |
| CXCR3 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Cxcr3 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Cxcr3 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| CXCR4 antagonist 1 |
|
|
|
|
|
|
|
|
| CXCR4 antagonist 10 |
|
|
|
|
|
|
|
99.27% |
| CXCR4 antagonist 2 |
|
|
|
|
|
|
|
|
| CXCR4 antagonist 3 |
|
|
|
|
|
|
|
|
| CXCR4 antagonist 4 |
|
|
|
|
|
|
|
|
| CXCR4 antagonist 5 |
|
|
|
|
|
|
|
|
| CXCR4 antagonist 6 |
|
|
|
|
|
|
|
|
| CXCR4 antagonist 7 |
|
|
|
|
|
|
|
|
| CXCR4 antagonist 8 |
|
|
|
|
|
|
|
|
| CXCR4 antagonist 9 |
|
|
|
|
|
|
|
|
| CXCR4 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| CXCR4 modulator-1 |
|
|
|
|
|
|
|
|
| CXCR4 modulator-2 |
|
|
|
|
|
|
|
|
| Cxcr4 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Cxcr4 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| CXCR4-IN-1 |
|
|
|
|
|
|
|
|
| CXCR4-IN-2 |
|
|
|
|
|
|
|
|
| CXCR4-IN-3 |
|
|
|
|
|
|
|
99.69% |
| CXCR6 antagonist 1 |
|
|
|
|
|
|
|
|
| CXCR6 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Cxcr6 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| Cxcr6 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
| CXCR7 antagonist-1 |
|
|
|
|
|
|
|
99.85% |
| CXCR7 antagonist-1 hydrochloride |
|
|
|
|
|
|
|
99.41% |
| CXCR7 modulator 1 |
|
|
|
|
|
|
|
99.27% |
| CXCR7 modulator 1 (Standard) |
|
|
|
|
|
|
|
|
| CXCR7 modulator 2 |
|
|
|
|
|
|
|
98.71% |
| Cyclic MKEY |
|
|
|
|
|
|
|
|
| Cyclic MKEY TFA |
|
|
|
|
|
|
|
98.47% |
| Danirixin |
|
|
|
|
|
|
|
98.19% |
| DOTA Conjugated JM#21 derivative 7 |
|
|
|
|
|
|
|
|
| DOTA-CXCR4-L |
|
|
|
|
|
|
|
|
| DV1 |
|
|
|
|
|
|
|
|
| DV1 TFA |
|
|
|
|
|
|
|
98.53% |
| E70K |
|
|
|
|
|
|
|
|
| Eltrekibart |
|
|
|
|
|
|
|
98.00% |
| Elubrixin |
|
|
|
|
|
|
|
|
| Elubrixin hydrochloride |
|
|
|
|
|
|
|
|
| Elubrixin tosylate |
|
|
|
|
|
|
|
98.14% |
| EMU-116 |
|
|
|
|
|
|
|
98.53% |
| EPI-X4 |
|
|
|
|
|
|
|
98.91% |
| FC131 |
|
|
|
|
|
|
|
|
| FC131 TFA |
|
|
|
|
|
|
|
99.87% |
| FTO-IN-17 |
|
|
|
|
|
|
|
|
| GPR35 agonist 1 |
|
|
|
|
|
|
|
99.89% |
| GSK699 |
|
|
|
|
|
|
|
98.80% |
| GSK812397 |
|
|
|
|
|
|
|
|
| HBP08 |
|
|
|
|
|
|
|
|
| HF50731 |
|
|
|
|
|
|
|
|
| HF51116 |
|
|
|
|
|
|
|
|
| HFB-100204 |
|
|
|
|
|
|
|
|
| Hit 14 |
|
|
|
|
|
|
|
|
| HL82624 |
|
|
|
|
|
|
|
|
| Hypoglaucin A |
|
|
|
|
|
|
|
|
| HZD37-5 |
|
|
|
|
|
|
|
|
| ICT5040 |
|
|
|
|
|
|
|
|
| IS4 |
|
|
|
|
|
|
|
|
| IT1t |
|
|
|
|
|
|
|
|
| IT1t dihydrochloride |
|
|
|
|
|
|
|
99.77% |
| KRH-1636 |
|
|
|
|
|
|
|
|
| KRH-3955 hydrochloride |
|
|
|
|
|
|
|
|
| KY1051 |
|
|
|
|
|
|
|
|
| Ladarixin |
|
|
|
|
|
|
|
99.95% |
| Ladarixin sodium |
|
|
|
|
|
|
|
99.84% |
| LIH383 |
|
|
|
|
|
|
|
|
| LIH383 TFA |
|
|
|
|
|
|
|
99.83% |
| LN5972 |
|
|
|
|
|
|
|
|
| LN6023 hydrochloride |
|
|
|
|
|
|
|
|
| LY-2624587 |
|
|
|
|
|
|
|
|
| LY2510924 |
|
|
|
|
|
|
|
99.85% |
| Mavorixafor |
|
|
|
|
|
|
|
99.66% |
| Mavorixafor hydrochloride |
|
|
|
|
|
|
|
99.64% |
| Mavorixafor trihydrochloride |
|
|
|
|
|
|
|
99.75% |
| MEDI-3185 |
|
|
|
|
|
|
|
|
| Minecoside |
|
|
|
|
|
|
|
99.86% |
| MK-1966 |
|
|
|
|
|
|
|
96.17% |
| ML 145 |
|
|
|
|
|
|
|
96.09% |
| ML 145 (Standard) |
|
|
|
|
|
|
|
|
| ML339 |
|
|
|
|
|
|
|
99.88% |
| Motixafortide |
|
|
|
|
|
|
|
99.76% |
| MSX-122 |
|
|
|
|
|
|
|
98.16% |
| MSX-127 |
|
|
|
|
|
|
|
99.68% |
| MSX-130 |
|
|
|
|
|
|
|
98.00% |
| Mz438 |
|
|
|
|
|
|
|
|
| Navarixin |
|
|
|
|
|
|
|
99.33% |
| NBI-74330 |
|
|
|
|
|
|
|
99.76% |
| Nef-M1 |
|
|
|
|
|
|
|
|
| NF279 |
|
|
|
|
|
|
|
98.5% |
| NI-0701 |
|
|
|
|
|
|
|
99.74% |
| NI-0801 |
|
|
|
|
|
|
|
99.19% |
| NIK-IN-3 |
|
|
|
|
|
|
|
|
| NOTA-NHS ester |
|
|
|
|
|
|
|
90.0% |
| NoxaBH3 |
|
|
|
|
|
|
|
|
| NUCC-390 |
|
|
|
|
|
|
|
98.01% |
| NUCC-390 dihydrochloride |
|
|
|
|
|
|
|
98.19% |
| NVP CXCR2 20 |
|
|
|
|
|
|
|
|
| Olaptesed pegol |
|
|
|
|
|
|
|
95.94% |
| Olaptesed pegol sodium |
|
|
|
|
|
|
|
95.94% |
| Olaptesed pegol sodium scrambled negative control |
|
|
|
|
|
|
|
|
| Olopatadine |
|
|
|
|
|
|
|
98.94% |
| Olopatadine-d6 |
|
|
|
|
|
|
|
|
| Paeoniflorin-6′-O-benzene sulfonate |
|
|
|
|
|
|
|
|
| pCXCL8-1aa |
|
|
|
|
|
|
|
98.13% |
| PD-1/PD-L1-IN-63 |
|
|
|
|
|
|
|
98.03% |
| PDE4D inhibitor 1 |
|
|
|
|
|
|
|
|
| Pentixafor |
|
|
|
|
|
|
|
99.60% |
| Pentixather |
|
|
|
|
|
|
|
|
| Peptide 78 |
|
|
|
|
|
|
|
98.13% |
| Peptide E5 |
|
|
|
|
|
|
|
|
| Peptide R |
|
|
|
|
|
|
|
|
| Peptide R analogue 10 |
|
|
|
|
|
|
|
|
| Peptide R TFA |
|
|
|
|
|
|
|
98.34% |
| Peptide R54 |
|
|
|
|
|
|
|
|
| Peptide R54 acetate |
|
|
|
|
|
|
|
99.88% |
| PF-06465469 |
|
|
|
|
|
|
|
99.48% |
| PF-06747143 |
|
|
|
|
|
|
|
|
| PF-06835375 |
|
|
|
|
|
|
|
97.71% |
| Polyphemusin II-Derived Peptide |
|
|
|
|
|
|
|
|
| PROTAC IRAK4 degrader-14 |
|
|
|
|
|
|
|
|
| PROTAC STING Degrader-2 |
|
|
|
|
|
|
|
|
| PS372424 |
|
|
|
|
|
|
|
|
| PS372424 hydrochloride |
|
|
|
|
|
|
|
95.03% |
| RCP168 |
|
|
|
|
|
|
|
|
| RIPK3-IN-3 |
|
|
|
|
|
|
|
95.98% |
| Rugocrixan |
|
|
|
|
|
|
|
99.54% |
| SB-265610 |
|
|
|
|
|
|
|
99.03% |
| SB-332235 |
|
|
|
|
|
|
|
98.7% |
| SB02024 |
|
|
|
|
|
|
|
99.70% |
| SB225002 |
|
|
|
|
|
|
|
99.90% |
| SCH 546738 |
|
|
|
|
|
|
|
98.67% |
| SCH 563705 |
|
|
|
|
|
|
|
99.86% |
| SCH-900875 |
|
|
|
|
|
|
|
98.16% |
| SDF-1α (human) |
|
|
|
|
|
|
|
|
| SDF-1α (human) TFA |
|
|
|
|
|
|
|
98.89% |
| SDNUM04 |
|
|
|
|
|
|
|
|
| SFB-AMD3465 |
|
|
|
|
|
|
|
|
| SLW131 |
|
|
|
|
|
|
|
|
| SMU-3k |
|
|
|
|
|
|
|
|
| Snail IN-1 |
|
|
|
|
|
|
|
98.27% |
| SQA1 |
|
|
|
|
|
|
|
|
| SRT3109 |
|
|
|
|
|
|
|
99.68% |
| SRT3190 |
|
|
|
|
|
|
|
99.77% |
| SSB-2548 |
|
|
|
|
|
|
|
|
| STING agonist-50 |
|
|
|
|
|
|
|
|
| STING-IN-18 |
|
|
|
|
|
|
|
|
| SX-517 |
|
|
|
|
|
|
|
99.90% |
| SX-576 |
|
|
|
|
|
|
|
|
| SX-682 |
|
|
|
|
|
|
|
99.64% |
| TAK-779 |
|
|
|
|
|
|
|
99.89% |
| Tanimilast |
|
|
|
|
|
|
|
99.71% |
| TBS6b |
|
|
|
|
|
|
|
|
| TC14012 |
|
|
|
|
|
|
|
99.77% |
| TC14012 TFA |
|
|
|
|
|
|
|
|
| TFAM activator 1 |
|
|
|
|
|
|
|
99.25% |
| TIQ-15 |
|
|
|
|
|
|
|
|
| TJX7 |
|
|
|
|
|
|
|
|
| TN14003 |
|
|
|
|
|
|
|
|
| trans-VUF25471 |
|
|
|
|
|
|
|
|
| TRK-530 sodium |
|
|
|
|
|
|
|
|
| UCUF-965 |
|
|
|
|
|
|
|
|
| UNBS5162 |
|
|
|
|
|
|
|
99.07% |
| USL311 |
|
|
|
|
|
|
|
99.82% |
| VB-85247 |
|
|
|
|
|
|
|
|
| Vimnerixin |
|
|
|
|
|
|
|
99.16% |
| vMIP-II (1-21) |
|
|
|
|
|
|
|
|
| vMIP-II (1-21) TFA |
|
|
|
|
|
|
|
|
| VUF 11222 |
|
|
|
|
|
|
|
99.91% |
| VUF10132 |
|
|
|
|
|
|
|
|
| VUF11207 |
|
|
|
|
|
|
|
99.98% |
| VUF11207 fumarate |
|
|
|
|
|
|
|
99.94% |
| VUF11207 TFA |
|
|
|
|
|
|
|
|
| VUF11211 |
|
|
|
|
|
|
|
|
| VUF11418 |
|
|
|
|
|
|
|
|
| VUF5834 |
|
|
|
|
|
|
|
|
| VX5 |
|
|
|
|
|
|
|
96.19% |
| WK500B |
|
|
|
|
|
|
|
|
| WZ811 |
|
|
|
|
|
|
|
99.80% |
| YU241279 |
|
|
|
|
|
|
|
99.58% |
| Zn-DPA-maytansinoid conjugate 1 |
|
|
|
|
|
|
|
|
| Ulocuplumab |
|
|
|
|
|
|
|
99.90% |
| Eldelumab |
|
|
|
|
|
|
|
99.50% |
| Quetmolimab |
|
|
|
|
|
|
|
99.9% |
| Baohuoside I |
|
|
|
|
|
|
|
99.94% |
| Microhelenin C |
|
|
|
|
|
|
|
99.55% |
| Hexaprofen |
|
|
|
|
|
|
|
|
| Burixafor |
|
|
|
|
|
|
|
|
| Plerixafor |
|
|
|
|
|
|
|
99.90% |
| Plerixafor-d4 |
|
|
|
|
|
|
|
|
| Herpetin |
|
|
|
|
|
|
|
|
| Nicotinamide N-oxide |
|
|
|
|
|
|
|
99.85% |
| Nicotinamide N-oxide (Standard) |
|
|
|
|
|
|
|
|
| Kynurenic acid |
|
|
|
|
|
|
|
99.93% |
| Kynurenic acid-d5 |
|
|
|
|
|
|
|
99.85% |
| Kynurenic acid sodium |
|
|
|
|
|
|
|
99.82% |
| Regaloside B |
|
|
|
|
|
|
|
99.90% |
| Reparixin |
|
|
|
|
|
|
|
99.99% |
| Reparixin L-lysine salt |
|
|
|
|
|
|
|
99.87% |
| Olopatadine hydrochloride |
|
|
|
|
|
|
|
99.83% |
| Olopatadine-d3 hydrochloride |
|
|
|
|
|
|
|
|
| Olopatadine-d6 hydrochloride |
|
|
|
|
|
|
|
|
| Plerixafor octahydrochloride |
|
|
|
|
|
|
|
99.09% |
| Corydalmine |
|
|
|
|
|
|
|
99.74% |
| Decursin |
|
|
|
|
|
|
|
99.92% |
| Decursin-d6 |
|
|
|
|
|
|
|
|
| Benzoylpaeoniflorin |
|
|
|
|
|
|
|
98.47% |
| Artemotil |
|
|
|
|
|
|
|
99.91% |
| Baminercept |
|
|
|
|
|
|
|
99.97% |